Steven J. Burakoff is a cancer specialist and the author of both Therapeutic Immunology (2001) and Graft-Vs.-Host Disease: Immunology, Pathophysiology, and Treatment (1990). He served as Director of The Tisch Cancer Institute at Mount Sinai (2007-2017), which was created in 2007 to focus on translational medicine. He is the Lillian and Henry M. Stratton Professor of Cancer Medicine at Mount Sinai Medical Center[1][2] as well as Dean for Cancer Innovation and Chief, Pediatric Oncology at the Icahn School of Medicine.[3][4]
He has received 84 grants as of 2020[6] in fields related to core administration, cancer, T-Cell activation and regulation, as well as various immunological studies.
Interleukin-3 (IL-3)-induced c-fos activation is modulated by Gab2-calcineurin interaction. Pyarajan S, Matejovic G, Pratt JC, Baksh S, Burakoff SJ. Journal of Biological Chemistry. 2008 PMID18586679
Lysine 144, a ubiquitin attachment site in HIV-1 Nef, is required for Nef-mediated CD4 down-regulation. Jin YJ, Cai CY, Zhang X, Burakoff SJ. Journal of Immunology 2008 PMID18523251
Prostaglandin E2 activates HPK1 kinase activity via a PKA-dependent pathway. Sawasdikosol S, Pyarajan S, Alzabin S, Matejovic G, Burakoff SJ. Journal of Biological Chemistry, 2007 PMID17895239
From bytes to bedside: data integration and computational biology for translational cancer research. Mathew JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B. PLoS Computational Biology, 2007 PMID17319736
A CD8/Lck transgene is able to drive thymocyte differentiation. Fragoso RC, Pyarajan S, Irie HY, Burakoff SJ. Journal of Immunology, 2006 PMID17056525
HIV Nef-mediated CD4 down-regulation is adaptor protein complex 2 dependent. Jin YJ, Cai CY, Zhang X, Zhang HT, Hirst JA, Burakoff SJ. Journal of Immunology, 2005 PMID16116206
CD4 phosphorylation partially reverses Nef down-regulation of CD4. Jin YJ, Zhang X, Boursiquot JG, Burakoff SJ. Journal of Immunology, 2004 PMID15494497
Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells. Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H, Linthicum DS, Burakoff SJ, Coons T, Bellgrau D, Modiano JF. Journal of Pharmacology and Experimental Therapeutics, 2004 PMID15231866
SOD2-deficiency anemia: protein oxidation and altered protein expression reveal targets of damage, stress response, and antioxidant responsiveness. Friedman JS, Lopez MF, Fleming MD, Rivera A, Martin FM, Welsh ML, Boyd A, Doctrow SR, Burakoff SJ. Blood, 2004 PMID15205258
Fratricide of CD8+ cytotoxic T lymphocytes is dependent on cellular activation and perforin-mediated killing. Su MW, Pyarajan S, Chang JH, Yu CL, Jin YJ, Stierhof YD, Walden P, Burakoff SJ. European Journal of Immunology, 2004 PMID15307178
Increasing T-cell age reduces effector activity but preserves proliferative capacity in a murine allogeneic major histocompatibility complex-mismatched bone marrow transplant model. Friedman JS, Alpdogan O, van den Brink MR, Liu C, Hurwitz D, Boyd A, Kupper TS, Burakoff SJ. Journal of the American Society of Blood and Marrow Transplantation, 2004 PMID15205666
Rapamycin-resistant proliferation of CD8+ T cells correlates with p27kip1 down-regulation and bcl-xL induction, and is prevented by an inhibitor of phosphoinositide 3-kinase activity. Slavik JM, Lim DG, Burakoff SJ, Hafler DA., Journal of Biological Chemistry, 2004 PMID14573608